Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1485-1508

  Moreau, Jacques Pierre ^a   Delavault, Patrick ^a   Blumberg, Joëlle ^a  

^a IPSEN   (France)

Author keywords

development; hormone therapy; prostate cancer LHRH agonist

Indexed keywords

ANTIANDROGEN; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; BUSERELIN; CYPROTERONE ACETATE; CYTOTOXIC AGENT; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; GOSERELIN; LEUPRORELIN; METASTIN; MITOXANTRONE; NAFARELIN; PAMIDRONIC ACID; PEPTIDE; PREDNISONE; RALOXIFENE; TOREMIFENE; TRIPTORELIN; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; BIOCHEMISTRY; BONE DEMINERALIZATION; BONE DENSITY; BONE METASTASIS; CANCER FATIGUE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEPRESSION; DISEASE COURSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MARKETING; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUID RETENTION; FRACTURE; GONAD DYSFUNCTION; GYNECOMASTIA; HOT FLUSH; HUMAN; LIBIDO DISORDER; LIPID METABOLISM; LONG TERM CARE; MEDLINE; META ANALYSIS; METASTASIS; MICROCAPSULE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; ORCHIECTOMY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OVULATION INHIBITION; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION; SUICIDE GENE THERAPY; SUSTAINED RELEASE FORMULATION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; COMBINED MODALITY THERAPY; DRUG DESIGN; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33751581744     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.018     Document Type: Review

References (138)

1. Aus G., Abbou C.C., Bolla M., et al., European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
2. Available at. National Comprehensive Cancer Network in partnership with the American Cancer Society. Prostate Cancer Treatment Guidelines for Patients-Version V. Accessed May 26, 2006 (September 2005). http://www.nccn.org/patients/patient-gls/_english/_prostate/contents.asp
3. AstraZeneca Annual Report and Form 20-F Information 2004 (May 26, 2006). http://www.astrazeneca.com/sites/7/imagebank/rypearticleparam511562/astr azeneca-2004
4. Accessed May 26, 2006. Commercial availability of QLT's Eligard® 6-month formulation brings new treatment option for advanced prostate cancer (February 17, 2005). http://www.bcbiotech.ca/News/MemberPress_Releases/pr02170501.asp Accessed May 26, 2006
5. Robertson J.F., and Blarney R.W. The use of gonadotrophinreleasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 39 (2003) 861-869
6. Carel J.C., Lahlou N., Jaramillo O., et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 87 (2002) 4111-4116
7. Barbieri R.L. Primary gonadotropin-releasing hormone agonist therapy for suspected endometriosis: A nonsurgical approach to the diagnosis and treatment of chronic pelvic pain. Am J Manag Care 3 (1997) 285-290
8. Mizutani T., Sugihara A., Nakamuro K., and Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 83 (1998) 1253-1255
9. Frydman R. Use of GnRH analogs in in vitro fertilization (IVF). In: Bouchard P., Haour F., Franchimont P., and Schalz B. (Eds). Recent Progress on GnRH and Gonadal Peptides: Proceedings of the International Symposium. Paris, France, 16-17 September 1989 (1990), Elsevier, New York, NY 261-271
10. Harris G.W. Neural Control of the Pituitary Gland (1955), E Arnold, London, UK 298
11. Schally A.V. Aspects of hypothalamic regulation of the pituitary gland with major emphasis on its implications for the control of reproductive processes. 1977. In: Lindsten J. (Ed). Nobel Lectures in Physiology or Medicine 1971-1980 (1992), World Scientific Publishing Co, Singapore
12. Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol 184 (2005) 11-28
13. Burgus R., Dunn T.F., Desiderio D., and Guillemin R. Molecular structure of the hypothalamic hypophysiotropic TRF factor of ovine origin: Mass spectrometry demonstration of the PCA-His_pro_NG2 sequence [in French]. C R Acad Sci Hebd Seances Acad Sci D 269 (1969) 1870-1873
14. Nair R.M., Barrett J.F., Bowers C.Y., and Schally A.V. Structure of porcine thyrotropin releasing hormone. Biochemistry 9 (1970) 1103-1106
15. Schally A.V., Arimura A., Kastin A.J., et al. Gonadotropinreleasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173 (1971) 1036-1038
16. Schally A.V., Arimura A., Baba Y., et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 43 (1971) 393-399
17. Baba Y., Matsuo H., and Schally A.V. Structure of the porcine LH- and FSHreleasing hormone II. Confirmation of the proposed structure by conventional sequential analyses. Biochem Biophys Res Commun 44 (1971) 459
18. Schally A.V., Kastin A.J., and Arimura A. Hypothalamic follicle-stimulating (FSH) and luteinizing hormone (LH)-regulating hormone: Structure, physiology, and clinical studies. Fertil Steril 22 (1971) 703-721
19. Schally A.V., Redding T.W., Matsuo H., and Arimura A. Stimulation of the FSH and LH release in vitro by natural and synthetic LH and FSH releasing hormone. Endocrinology 90 (1972) 1561-1567
20. Arimura A., Debeljuk L., and Schally A.V. Stimulation of FSH release in vivo by prolonged infusion of synthetic LH-RH. Endocrinology 91 (1972) 529-532
21. Coy D.H., Seprodi J., Vilchez-Martinez J.A., et al. Structure-function studies and prediction of conformational requirements for LH-RH. In: Collu R., Barbeau A., Ducharme J.A., and Rochefort J.G. (Eds). Central Nervous System Effects of Hypothalamic Hormones and Other Peptides (1979), Raven Press, New York, NY 317-323
22. Redding T.W., Kastin A.J., Gonzales-Barcena D., et al. The half-life, metabolism and excretion of titrated luteinizing hormone-releasing hormone (LH-RH) in man. J Clin Endocrinol Metab. 37 (1973) 626-631
23. Schally A.V., Coy D.H., and Arimura A. LHRH agonists and antagonists. Int J Gynaecol Obstet 18 (1980) 318-324
24. Merrifield R.B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85 (1963) 2149-2154
25. Yalow R.S., and Berson S.A. Assay of plasma insulin in human subjects by immunological methods. Nature 184 (1959) 1648-1649
26. Moss R.L., and McCann S.M. Induction of mating behavior in rats by luteinizing hormone-releasing factor. Science 181 (1973) 177-179
27. Schally A.V., Steelman S.L., and Bowers C.Y. Effect of hypothalamic extracts on release of growth hormone in vitro. Proc Soc Exp Biol Med 119 (1965) 208-212
28. Schaison G. Gonadotropin-releasing hormone (GnRH) generalities. In: Bouchard P., Haour F., Franchimont P., and Schalz B. (Eds). Recent Progress on GnRH and Gonadal Peptides (1990), Elsevier Paris, Paris, France 15-24
29. Amoss Jr. M.S., and Guillemin R. Elevation of plasma LH concentrations induced by LH-releasing factor as measured by radioimmunoassay in the sheep. Endocrinology 84 (1969) 1517-1520
30. Arimura A., Sato H., Kumasaka T., et al. Production of antiserum to LHreleasing hormone (LH-RH) associ ated with gonadal atrophy in rabbits: Development of radioimmunoassays for LH-RH. Endocrinology 93 (1973) 1092-1103
31. Auclair C., Kelly P.A., Labrie F., et al. Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormonereleasing hormone agonist of human chorionic gonadotropin. Biochem Biophys Res Commun 76 (1977) 855-862
32. Belchetz P.E., Plant T.M., Nakai Y., et al. Hypophysial responses to continuous and intermittent delivery of hy popthalamic gonadotropin-releasing hormone. Science 202 (1978) 631-633
33. Labrie F., Belanger A., Cusan L., et al. Antifertility effects of LHRH agonists in the male. J Androl. 1 (1980) 209-228
34. Redding T.W., and Schally A.V. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A 78 (1981) 6509-6512
35. Nicholson R.I., Walker K.J., and Maynard P.V. Anti-tumour potential of a new luteinizing hormone releasing hormone analogue, ICI 118630. Eur J Cancer Suppl 1 (1980) 295-299
36. 210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men. J Steroid Biochem 13 (1980) 123-126
37. Smith R., Donald R.A., Espiner F.A., et al. Normal adults and subjects with hypogonadotropic hypogonadism respond differently to D-Ser(TBU)6LH-RH-EA10. J Clin Endocrinol Metab 48 (1979) 167-170
38. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
39. Huggins C., Stevens Jr. R.E., and Hodges C.V. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
40. Labrie F., Dupont A., Belanger A., et al. New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5 (1982) 267-275
41. Tolis G., Ackman D., Stellos A., et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 79 (1982) 1658-1662
42. Kerle D., Williams G., Ware H., and Bloom S.R. Failure of long term luteinising hormone releasing hormone treat ment for prostate cancer to suppress serum luteinising hormone and testosterone. Br Med J (Clin Res Ed) 289 (1984) 468-469
43. Available at. Southern Research Institute. Pharmaceutical sciences: Drug delivery and GMP. Accessed (May 26, 2006). http://www.southernresearch.org/pharmaceutical/drug-delivery
44. Asch R.H., Rojas F.J., Tice T.R., and Schally A.V. Studies of a controlled-release microcapsule formulation of an LH RH agonist (D Trp-6-LH-RH) in the rhesus monkey menstrual cycle. Int J Fertil 30 (1985) 19-26
45. Redding T.W., Schally A.V., Tice T.R., and Meyers W.E. Long-acting delivery systems for peptides: Inhibition of rat prostate tumors by controlled release of [D Trp6]luteinizing hormonereleasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A 81 (1984) 5845-5848
46. Abstract. Vickery B., McRae G., and Tallentire D. Disparate effects of daily versus continuous administration of a po tent LH-RH agonist on plasma LH levels in female rhesus monkeys. Fertil Steril 39 (1983) 417-418
47. Furr B.J., and Hutchinson F.G. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumors. Prog Clin Biol Res 185A (1985) 143-153
48. Decapeptyl®. Trelstar®/Decapeptyl® (May 26, 2006)
49. Shearer R.J., Hendry W.F., Sommerville I.F., and Fergusson J.D. Plasma testosterone: An accurate monitor of hor mone treatment in prostatic cancer. Br J Urol 45 (1973) 668-677
50. Parmar H., Phillips R.H., Lightman S.L., and Edwards L. How would you like to have an orchidectomy for advanced prostatic cancer?. Am J Clin Oncol 11 (1988) S160-S168
51. Oefelein M.G., Feng A., Scolieri M.J., et al. Reassessment of the definition of castrate levels of testosterone: Impli cations for clinical decision making. Urology 56 (2000) 1021-1024
52. Schally A.V. Luteinizing hormonereleasing hormone analogs: Their impact on the control of tumorigenesis. Peptides 20 (1999) 1247-1262
53. Ahmed S.R., Grant J., Shalet S.M., et al. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. Br Med J (Clin Res Ed) 290 (1985) 185-187
54. Quebec City, Canada. Abstract 2055. Roger M., Duchier J., Lahlou N., et al. Treatment of prostatic tumors by the LH-RH agonist D-Tryp6-LH-RH: Efficacy of a long-acting form upon testosterone, LH and D-Tryp6-LHRH plasma levels. Presented at: Seventh International Congress of Endocrinology (July 1-7, 1984)
55. Walker K.J., Turkes A.O., Turkes A., et al. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex). J Endocrinol 103 (1984) R1-R4
56. Parmar H., Phillips R.H., Lightman S.L., et al. Randomised controlled study of orchidectomy vs long-acting D Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 2 (1985) 1201-1205
57. Botto H., Richard F., Mathieu F., and De Mouzon J. Randomized multicenter trial: Triptorelin vs surgical castra tion, long term results and prognostic factors. Proceedings of the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment (1994), Karger, Paris, France 307-314
58. De Sy W.A., De Wilde P., De Meyer J.M., et al. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy. Acta Urol Belg 56 (1988) 581-588
59. [published correction appears in Ann Intern Med. 2005;143:764-765]. Seidenfeld J., Samson D.J., Hasselblad V., et al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 132 (2000) 566-577
60. Samson D.J., Seidenfeld J., Schmitt B., et al. Systematic review and meta analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 (2002) 361-376
61. Prostate Cancer Trial ists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 355 (2000) 1491-1498
62. Bennett C.L., Tosteson T.D., Schmitt B., et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A metaanalysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 2 (1999) 4-8
63. Teillac P., Bono A.V., Irani J., et al. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: Considerations for optimal use. Clin Ther 27 (2005) 273-285
64. Available at:. American Cancer Society. Cancer facts and figures 2005. Accessed (May 26, 2006). http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_FactsFigures_200 5.asp.
65. Roscigno M., Sangalli M., Mazzoccoli B., et al. Medical therapy of prostate cancer. A review. Minerva Urol Nefrol 57 (2005) 71-84
66. Cox R.L., and Crawford E.D. Estrogens in the treatment of prostate cancer. J Urol 154 (1995) 1991-1998
67. Loblaw D.A., Mendelson D.S., Talcott J.A., et al., American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22 (2004) 2927-2941
68. Agarwal D.K., Costello A.J., Peters J., et al. Differential response of prostate specific antigen to testosterone surge after luteinizing hormonereleasing hormone analogue in prostate cancer and benign prostatic hyperplasia. BJU Int 85 (2000) 690-695
69. Labrie F., Belanger A., Luu-The V., et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26 (2005) 361-379
70. Grossmann M.E., Huang H., and Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93 (2001) 1687-1697
71. Armstrong A.J., and Carducci M.A. Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies. Curr Oncol Rep 7 (2005) 220-227
72. Moore C.N., and George D.J. Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol 15 (2005) 157-162
73. Tannock I.F., de Wit R., Berry W.R., et al., TAX 327 Investigators. Docetaxel plus prednisone or mito xantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
74. Gee W.F., Holtgrewe H.L., Albertsen P.C., et al. Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol 154 (1995) 207-208
75. Mongiat-Artus P., and Teillac P. Role of luteinising hormone releasing hormone (LHRH) agonists and hormonal treatment in the management of prostate cancer. Eur Urol Suppl 4 (2005) 4-13
76. Carter H.B., and Partin A.W. Diagnosis and staging of prostate cancer. In: Walsh P.C., Retik A.B., Vaughan E.D., et al. (Eds). Campbell's Urology. 8th ed (2002), Elsevier Science, New York, NY 3055-3079
77. Gleason D.F. The Veterans Administration Cooperative Urological Research Group: Histological grading and clinical staging of prostatic carcinoma. In: Tannenbaum M. (Ed). UrologicPathology: The Prostate (1977), Lea & Febiger, Philadelphia, Pa 171-197
78. Labrie F., Candas B., Gomez I.L., and Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology 60 (2002) 115-119
79. Evans C.P., Fleshner N., Fitzpatrick J.M., and Zlotta R. An evidence-based approach to understanding the phar macological class effect in the management of prostatic diseases. BJU W 95 (2005) 743-749
80. Labrie F., Cusan L., Gomez J.L., et al. Neoadjuvant hormonal therapy: The Canadian experience. Urology 49 Suppl 3A (1997) 56-64
81. Scolieri M.J., Altman A., and Resnick M.I. Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review. Is it indicated?. J Urol 164 (2000) 1465-1472
82. Blute M.L., Bergstralh E.J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165 (2001) 119-125
83. Pisansky T.M. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer. Urology 62 Suppl 1 (2003) 36-45
84. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
85. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86 10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
86. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
87. [published correction appears in J Clin Oncol. 2004;22:386]. Hanks G.E., Pajak T.F., Porter A., et al., Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
88. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
89. Vallett B.S. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Delaware Med J 16 (1944) 19-20
90. Labrie F., Cusan L., Gomez J.L., et al. Down-staging of early stage prostate cancer before radical prostatecto my: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44 (1994) 29-37
91. Hugosson J., Abrahamsson P.A., Ahlgren G., et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neoadjuvant hormone treatment. Eur Urol 29 (1996) 413-419
92. Soloway M.S., Sharifi R., Wajsman Z., et al., Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 154 (1995) 424-428
93. Witjes W.P., Schulman C.C., Debruyne F.M., and European Study Group on Neoadjuvant Treatment of Prostate Cancer. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma. Urology 49 Suppl 3A (1997) 65-69
94. Aus G., Abrahamsson P.A., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU Int 90 (2002) 561-566
95. Soloway M.S., Pareek K., Sharifi R., et al., Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-Year results. J Urol 167 (2002) 112-116
96. Schulman C.C., Debruyne F.M., Forster G., et al., European Study Group on Neoadjuvant Treatment of Prostate Cancer. 4-Year followup results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3NOMO prostate cancer. Eur Urol 38 (2000) 706-713
97. Van Poppel H. Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out. Eur Urol 39 Suppl 1 (2001) 10-14
98. Cheng L., Zincke H., Blute M.L., et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66-73
99. Abstract 1480. Messing E., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: Results at 10 years of EST 3886. J Urol 169 (2003) 396
100. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council Trial. Br J Urol 79 (1997) 235-246
101. Abstract 1574. Reynolds W., Wu J., Sun L., et al. Comparison of early versus late hormonal therapy (HT) following early PSA-only recurrence (ePSAR) within the Department of Defense CenterforProstate Disease Research database. Proc Arn Soc Clin Oncol. 22 (2003) 392
102. Whelan P. Hormone therapy in prostate cancer-moving into the 21st century. Eur Urol Suppl 4 (2005) 53-56
103. Higano C.S. Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity. Urology 61 (2003) 32-38
104. Mottet N., Prayer-Galetti T., Hammerer P., et al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98 (2006) 20-27
105. Cherrier M.M., Rose A.L., and Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol 170 (2003) 1808-1811
106. Bruchovsky N., Klotz L.H., Sadar M., et al. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol 4 (2000) 191-199
107. Higano C., Shields A., Wood N., et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64 (2004) 1182-1186
108. Pether M., Goldenberg S.L., Bhagirath K., and Gleave M. Intermittent androgen suppression in prostate cancer: An update of the Vancouver experience. Can J Urol 10 (2003) 1809-1814
109. Available at:. Southwest Oncology Group. SWOG9346. Intermittent androgen deprivation in patients with stage D2 prostate cancer, phase III. Accessed (May 26, 2006). http://www.swog.org/visitors/ViewProtocolDetails.asp?ProtocolID=17
110. Available at:. Southwest Oncology Group. Protocol JPR7. Intergroup (NCIC, SWOG) phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with prostate-specificantigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer. Accessed (May 26, 2006). http://swog.org/visitors/ViewProtocolDetails.asp?ProtocolID=82
111. Available at:. European Organisation for Research and Treatment of Cancer. EORTC protocol 30985. Intermittent an drogen deprivation in patients with stage D2 prostate cancer-phase III. Accessed (May 26, 2006). http://www.eortc.be/protoc/Details.asp?Protocol-30985
112. Mcleod D.G. Hormonal therapy: Historical perspective to future directions. Urology 61 Suppl 1 (2003) 3-7
113. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Increasing use of gonadotropinreleasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103 (2005) 1615-1624
114. discussion 99-100. Saad F. Bone loss in prostate cancer: Evaluation, treatment and prevention. Can J Urol 12 (2005) 71-76
115. Smith M.R. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60 (2002) 79-85
116. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation thera py for prostate cancer. J Urol 163 (2000) 181-186
117. Oefelein M.G., Ricchiuti V., Conrad W., and Resnick M.I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 (2002) 1005-1007
118. Smith M.R. Diagnosis and management of treatment- related osteoporosis in men with prostate carcinoma. Cancer 97 (2003) 789-795
119. Rogers M.J., Gordon S., Benford H.L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 Suppl 12 (2000) 2961-2978
120. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012
121. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
122. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882
123. Smith M.R., Fallon M.A., Lee H., and Finkelstein J.S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 3841-3846
124. Smith M.R. Therapy insight: Osteoporosis during hormone therapyfor prostate cancer. Nat Clin Pract Urol 2 (2005) 608-615
125. In a Phase III lipid interim analysis, Acapodene treatment lowered cholesterol and raised HDL in prostate cancer patients on androgen deprivation therapy (September 2, 2006). http://www.psa-rising.com/wiredbird/gtx
126. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res 20 (2005) 2275-2282
127. Boxer R.S., Kenny A.M., Dowsett R., and Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 8 (2005) 207-212
128. Smith M.R., Finkelstein J.S., McGovern F.J., et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 (2002) 599-603
129. Jenkins V.A., Bloomfield D.J., Shilling V.M., and Edginton T.L. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int 96 (2005) 48-53
130. Litwin M.S., Saigal C.S., Lubeck D.P., et al. Health-related quality of life in men with metastatic prostate cancer: The misleading effect of lead-time bias. BJU Int 91 (2003) 9-13
131. Halmos G., Arencibia J.M., Schally A.V., et al. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 163 (2000) 623-629
132. Nagy A., Schally A.V., Armatis P., et al. Cytotoxic analogs of luteinizing hormone-releasing hormone con taining doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA. 93 (1996) 7269-7273
133. Schally A.V., and Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 72 (2003) 2305-2320
134. Schally A.V., and Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trend Endocrinol Metab 15 (2004) 300-310
135. Stangelberger A., Schally A.V., Nagy A., et al. Inhibition of human experimental prostate cancers by a tar geted cytotoxic luteinizing hormonereleasing hormone analog AN-207. Prostate 66 (2006) 200-210
136. Navarro V.M., Castellano J.M., Fernandez-Femandez R., et al. Effects of KiSST peptide, the natural ligand of GPR54, on follicle-stimulating hormone secretion in the rat. Endocrinology 146 (2005) 1689-1697
137. Smith J.T., Dungan H.M., Stoll F.A., et al. Differential regulation of KiSS-1 mRNA expression by sex steroids in the brain of the male mouse. Endocrinology 146 (2005) 2976-2984
138. Gotoh A., Shirakawa T., Wada Y., et al. Gene therapy. Ninyokika Kiyo 51 (2005) 75-79